JAK1 inhibitors modulate the innate and adaptive immune responses involved in IBD by blocking JAK-mediated inflammatory pathways, thereby reducing chronic gastrointestinal inflammation (59). The gene discussed is JAK1; the disease is inflammatory bowel disease.